



Dicerna to Participate in Two Upcoming Investor Conferences

September 24, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 24, 2018-- [Dicerna Pharmaceuticals, Inc.](#) (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in October.

- 2018 Cantor Fitzgerald Global Healthcare Conference, Monday, October 1, 2018 at 7:45 a.m. ET at the InterContinental New York Barclay in New York. Dr. Fambrough will present a corporate update and overview of the Company's most advanced GalXC™ pipeline programs, including DCR-PHXC, an investigational RNAi therapeutic in development for the treatment of all forms of primary hyperoxaluria. A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.
- Leerink Partners Roundtable Series: Rare Disease and Oncology, Tuesday, October 2, 2018 at 2:30 p.m. ET at the Lotte New York Palace in New York. Dr. Fambrough will participate in an analyst-moderated fireside chat. A live webcast of the fireside chat can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180924005170/en/>

Source: Dicerna Pharmaceuticals, Inc.

Investors:

Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

or

Media:

SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com